NCT02708914View on ClinicalTrials.gov

Study to Compare the Safety and Efficacy of UB-851 and Eprex®

PHASE3CompletedINTERVENTIONAL
Enrollment

269

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
Renal Anemia
Interventions
BIOLOGICAL

UB-851

UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.

BIOLOGICAL

Eprex

Eprex® is chosen as the comparator.

All Listed Sponsors
lead

UBI Pharma Inc.

INDUSTRY

NCT02708914 - Study to Compare the Safety and Efficacy of UB-851 and Eprex® | Biotech Hunter | Biotech Hunter